With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
Educational research only - not investment advice, an offer, or a trade instruction. Confirm current data and do your own due diligence before acting.
Altria represents a pure-play cash cow in structural decline, heavily dependent on aggressive pricing to mask secular volume erosion while funding an outsized dividend payout.
A rapid acceleration in smoking volume declines coupled with draconian FDA intervention could compress revenueRevenueRevenue is an income-statement line item used to reconcile revenue to operating profit, pre-tax income, net income, or per-share earnings. It should be compared across periods and against peer disclosure conventions. below the break-even threshold for current dividend levels.
The FDA finalizes and enforces a strict ban on menthol cigarettes, materially impacting Altria's volume and revenue with limited transition to smoke-free alternatives.
Federal mandate to reduce nicotine in combustible cigarettes to minimally addictive levels, effectively destroying the core product's value proposition.
NJOY and on! fail to gain meaningful market share against entrenched competitors like ZYN, leaving the company completely reliant on a dying combustible market.
| Line item | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
|---|---|---|---|---|---|---|
| Revenue | $21.11B | $20.69B-2.0% | $20.50B-0.9% | $20.44B-0.3% | $20.14B-1.5% | -1.2% |
| Gross profit | $13.99B | $14.25B | $14.28B | $14.37B | $14.54B | +1.0% |
| Operating income | $11.56B | $11.92B | $11.55B | $11.63B | $12.04B | +1.0% |
| Net income | $2.48B | $5.76B+132.3% | $8.13B+41.1% | $11.26B+38.5% | $6.95B-38.3% | +29.4% |
| EPS (diluted) | — | $3.19 | $4.57 | $6.54 | $4.12 | +6.6% |
| EBITDA | $5.26B | $8.74B | $12.35B | $15.07B | $10.83B | +19.8% |
| R&D | — | — | — | — | — | — |
| SG&A | $2.43B | $2.33B | $2.74B | $2.74B | $2.51B | +0.8% |
Cash-flow quality is reflected in the OCFOperating cash flowCash generated from the company's core operations after working-capital changes but before capital expenditures. The first line of the cash-flow statement. / net incomeNet IncomeNet Income is an income-statement line item used to reconcile revenue to operating profit, pre-tax income, net income, or per-share earnings. It should be compared across periods and against peer disclosure conventions., accounting-quality, and ROICROICReturn on invested capital. Operating profit (after tax) divided by invested capital. The single best gauge of capital-efficiency. Spread over WACC = economic value created. rows above.
Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.
| Deterioration versus the report thesis |
| Free cash flow dropping below the required dividend payout threshold. | Monitor | Deterioration versus the report thesis |
| Regulatory announcements advancing the timeline for menthol or nicotine bans. | Monitor | Deterioration versus the report thesis |
